NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
A Multi-centre, Prospective, Observational Study on Effectiveness and Safety of ZOLADEX® (Goserelin Acetate Implant) 10.8 mg and ZOLADEX® (Goserelin Acetate Implant) 3.6 mg in Chinese Patients With Localized or Locally Advanced Hormonal Treatment -naïve Prostate Cancer
A Multi-centre, Prospective, Observational Study on Effectiveness and Safety of ZOLADEX® (Goserelin Acetate Implant) 10.8 mg and ZOLADEX® (Goserelin Acetate Implant) 3.6 mg in Chinese Patients With Localized or Locally Advanced Hormonal Treatment -naïve Prostate Cancer
CompletedN/A
Sponsor: AstraZeneca
Conditions: Localized or Locally Advanced Prostate Cancer
Countries: China
This study is a multi-centre, prospective observational study. The study plans to enrol 500 patients with localized or locally advanced prostate cancer who are eligible and intended to be prescribed Zoladex® (goserelin acetate implant) 10.8 mg or Zoladex® (goserelin acetate implant) 3.6 mg as monotherapy or in combination with androgen blockade (CAB) at 50 clinical sites in China. The effectiveness and safety data will be collected at baseline and each visit within 26 weeks after treatment of Zoladex®.
Eligibility overview
Sex: MALE
Age: 18 Years to 100 Years
Healthy volunteers: No
Study type: OBSERVATIONAL
Eligibility criteria
Inclusion Criteria: 1. Ability to provide informed consent, complete all study assessments and have complete medical record; 2. Male aged 18 years and over; 3. Diagnosis of localized or locally advanced prostate cancer requiring immediate hormonal therapy; 4. Being prescribed Zoladex ® (goserelin acetate implant) 10.8 mg or Zoladex ® (goserelin acetate implant) 3.6 mg in accordance with the terms of marketing authorization as monotherapy or in combination with androgen blockade (CAB); 5. More than 26 weeks' life expectancy; Exclusion Criteria: 1. Patients who are planned to receive radiation therapy; 2. Patients with hypersensitivity to LHRH, its analogues, or any components of goserelin depot; 3. Previous or concurrent hormonal therapy including surgical castration, androgen blockers, oestrogen therapy, or other LHRH agonists.
Locations (25)
- Beijing, China
- Beijing, China
- Chengdu, China
- Foshan, China
- Guangdong, China
- Guangzhou, China
- Guangzhou, China
- Hangzhou, China
- Harbin, China
- Jinan, China
- Jinan, China
- Langfang, China
- Nanjing, China
- Nanjing, China
- Ningbo, China
- Shanghai, China
- Shanghai, China
- Shijiazhuang, China
- Ürümqi, China
- Wuhan, China
- Wuhan, China
- Wuhan, China
- Xi'an, China
- Yantai, China
- Zhuhai, China